Celldex Therapeutics Inc. (CLDX): Today's Featured Drugs Laggard
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.3%. By the end of trading, Celldex Therapeutics fell $0.40 (-2.0%) to $19.55 on average volume. Throughout the day, 1,715,986 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 1,860,800 shares. The stock ranged in price between $19.20-$20.33 after having opened the day at $20.23 as compared to the previous trading day's close of $19.95. Other companies within the Drugs industry that declined today were:
(
), down 34.5%,
(
), down 28.0%,
(
), down 11.6% and
(
), down 8.1%.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $1.6 billion and is part of the health care sector. Shares are up 197.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.
TheStreet Ratings rates
Celldex Therapeutics
as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.
- You can view the full Celldex Therapeutics Ratings Report.
On the positive front,
(
), up 16.8%,
(
), up 15.8%,
(
), up 15.7% and
Bacterin International Holdings
(
), up 14.9% , were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null